Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Catalent Inc (NY: CTLT )

59.92 -0.03 (-0.05%)
Official Closing Price Updated: 4:00 PM EST, Nov 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,610,529
Open 60.01
Bid (Size) 59.60 (2)
Ask (Size) 61.85 (2)
Prev. Close 59.95
Today's Range 59.85 - 60.21
52wk Range 32.38 - 61.20
Shares Outstanding 170,341,553
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Catalent, Inc. Reports First Quarter Fiscal 2025 Results
From Catalent, Inc.
Via Business Wire
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition. 
Via Benzinga

Performance

YTD
+33.01%
+33.01%
1 Month
-1.14%
-1.14%
3 Month
+0.67%
+0.67%
6 Month
+6.62%
+6.62%
1 Year
+72.09%
+72.09%

More News

Read More
Catalent Issues Open Letter to Customers Regarding Pending Acquisition by Novo Holdings
From Catalent, Inc.
Via Business Wire
After US Senator, Unions Urge Federal Trade Commission To Block Novo's $16.5B Acquisition Of Catalent
Via Benzinga
Beyond The Numbers: 6 Analysts Discuss Catalent Stock
Via Benzinga
Jim Cramer: 'We Need More Uranium,' Recommends This Stock; Says Novo Nordisk 'Doesn't Hold A Candle' To Big Pharma Rival
Via Benzinga
Catalent Signs Agreement to Sell Somerset, NJ Oral Solids Facility
From Catalent, Inc.
Via Business Wire
FTC Faces Pressure to Block Novo Nordisk-Catalent Merger Over Antitrust Fears
Via Benzinga
Four Stocks To Watch This Week - Tuesday, Oct. 01
Via Talk Markets
Tempus AI Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
Catalent, Inc. Reports Fourth Quarter and Fiscal 2024 Results
From Catalent, Inc.
Via Business Wire
Prediction: Up 74% So Far This Year, This Weight Loss Stock Is About to Crater
Via The Motley Fool
Catalent Completes $25 Million Expansion of its Clinical Supply Facility in Schorndorf, Germany
From Catalent, Inc.
Via Business Wire
Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty
Via Benzinga
S&P 500 Giants Lead Five Healthy Stocks Near Buy Points
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Catalent Stockholders Approve Transaction with Novo Holdings
From Catalent, Inc.
Via Business Wire
Soaring Eli Lilly Stock Could Climb Another 24% According to a Wall Street Analyst. Is the Stock a Buy Now?
Via The Motley Fool
Hedge Funds Tweak Portfolios In Q1: Marvell, TD Synnex, AES Get More Love As Focus Shifts To AI
Via Benzinga
CTLT Stock Earnings: Catalent Misses EPS, Misses Revenue for Q3 2024
Via InvestorPlace
Catalent, Inc. Reports Third Quarter Fiscal 2024 Results
From Catalent, Inc.
Via Business Wire
Demand Soars For Novo Nordisk's Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly Competition
Via Benzinga
Robbins LLP Reminds Stockholders it is Investigating the Acquisition of Catalent, Inc. (CTLT)
From Robbins LLP
Via Business Wire
Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating
Via Benzinga
Robbins LLP is Investigating the Acquisition of Catalent, Inc. (CTLT) by Novo Holdings
From Robbins LLP
Via GlobeNewswire
Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.